Gossamer Bio, Inc. (GOSS) Stock Price & Analysis

Gossamer Bio, Inc. (GOSS) fell 3.38% to USD 0.16 as of June 9, 2026 at 23:49 UTC, according to Nexqual real-time market data.

GOSS last closed at USD 0.17; the session ranged USD 0.15–0.17 on volume of 12,886,319 shares. Market capitalization is $78.22M, with a 52-week range of USD 0.15–3.87 (NMS). Source: Nexqual, June 9, 2026 at 23:49 UTC.

Key Statistics (as of June 9, 2026 at 23:49 UTC)

Technical Analysis (GOSS)

Nexqual's technical model rates GOSS "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 23:49 UTC.

Analyst Ratings (GOSS)

Wall Street analysts rate GOSS "Hold" based on 5 analysts, with a mean price target of USD 4.46 (range USD 0.28–15), per Nexqual as of June 9, 2026 at 23:49 UTC.

Earnings (GOSS)

Recent Earnings History

Source: Nexqual, June 9, 2026 at 23:49 UTC.

Financials & Fundamentals (GOSS)

Source: Nexqual, June 9, 2026 at 23:49 UTC.

Financial Health Score (GOSS)

Nexqual rates Gossamer Bio, Inc.'s overall financial health "Weak" across five dimensions, as of June 9, 2026 at 23:49 UTC.

Ownership (GOSS)

Source: Nexqual, June 9, 2026 at 23:49 UTC.

Leadership (GOSS)

Gossamer Bio, Inc. is led by Faheem Hasnain (age 67), Co-Founder, CEO, President & Chairman, per Nexqual as of June 9, 2026 at 23:49 UTC.

Major Backers & Investors (GOSS)

Notable institutional backers of Gossamer Bio, Inc. include Kalehua Capital Management LLC, AQR Capital Management, LLC, Arch Venture Management, Llc, according to Nexqual as of June 9, 2026 at 23:49 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 9, 2026 at 23:49 UTC.

From Gossamer Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)

Key Strengths & Strategy (as disclosed to the SEC)

• We are completing analyses of the PROSERA dataset and plan to engage with the FDA, including through requesting a Type C meeting, to understand their perspective on the totality of the PROSERA and TORREY datasets and potential regulatory paths forward. • Advance preparations toward a potential NDA submission.
• The collaboration is focused on the development and commercialization of seralutinib and licensed products including seralutinib and related licensed compounds, or Licensed Products, in the United States and the rest of the world, or the ROW Territory, for the treatment of PAH and PH-ILD and other indications, as may be permitted under the collaboration agreement.
• We also rely on trade secrets and know-how relating to our proprietary technology and product candidates and continuing innovation to develop, strengthen and maintain our proprietary position.
• Our commercial success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions and improvements; to preserve the confidentiality of our trade secrets; to defend and enforce our proprietary rights, including any patents that we may own in the future; and to operate without infringing on the valid and enforceable patents and other proprietary rights of third parties.

Partnerships

• We may also seek to raise additional capital through equity offerings, debt financings or other capital sources to support our strategic priorities. • Advance RT234 under our option agreement with Respira in a capital‑efficient manner.
• We intend to continue advancing RT234 pursuant to our option agreement with Respira Therapeutics, which is structured to support limited foundational manufacturing and device readiness activities while preserving our focus and operational resources for seralutinib.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:49 UTC. This page is informational and not investment advice.